Cardurion Pharmaceuticals, Inc. — Form D
Cardurion Pharmaceuticals, Inc. of BURLINGTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2024-07-24. The offering totals $260.4M, of which $260.4M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-07-24
- Form: D
- Accession: 0001702453-24-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $260.4M
- Amount sold: $260.4M
- Investors: 19
- Date of first sale: 2024-07-10
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-519629
Issuer
- Name: Cardurion Pharmaceuticals, Inc.
- CIK: 0001702453
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 78 BLANCHARD ROAD, SUITE 200, BURLINGTON, MA, 01803
- Phone: 617-996-1433
Officers, directors & promoters (14)
| Name | Role | Location |
|---|
| Nicholas Downing | Director | Mountain View, CA |
| Jeb Keiper | Director | Boston, MA |
| Adam Koppel | Director | Boston, MA |
| Peter Lawrence | Director | New York, NY |
| Daniel Lynch | Director | Greenfield, IN |
| Edward Mathers | Director | South San Francisco, CA |
| Michael Mendelsohn | Director | Cambridge, MA |
| Evan Rachlin | Director | San Diego, CA |
| Emma Reeve | Director | Norfolk, VA |
| Peter Lawrence | Executive Officer | New York, NY |
| Michael Mendelsohn | Executive Officer | Cambridge, MA |
| Amy Schulman | Director | Cambridge, MA |
| Keith Gottesdiener | Director | Burlington, MA |
| Kenneth Novack | Director | Burlington, MA |
Other filings by this issuer (5)
More